HIT Consultant June 30, 2022
What You Should Know:
– The traditional approach to fostering biopharma growth is no longer sustainable, according to Accenture research and analysis. The new research reveals perspectives on the life sciences industry based on an extensive analysis of over 300 M&A deals made by the top 30 biopharma companies between 2010–2021.
– The analysis reveals multiple factors are eroding the sustainability of an inorganic growth strategy, such as rising costs of M&A, declining ability to pay and new challengers. However, the pace of innovation in life sciences is at an all-time high.
Inorganic Growth Strategy
With biopharmas continuing to develop capabilities through i.e. AI and analytics, we’re experiencing an exciting and accelerated pace of innovation. Traditionally, biopharma companies have relied...
Today's Sponsors
Today's Sponsor